- Home
- RMBI vs ADCT Comparison
RMBI vs ADCT Comparison
Compare RMBI & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMBI
- ADCT
- Stock Information
- Founded
- RMBI 1887
- ADCT 2011
- Country
- RMBI United States
- ADCT Switzerland
- Employees
- RMBI N/A
- ADCT N/A
- Industry
- RMBI Major Banks
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- RMBI Finance
- ADCT Health Care
- Exchange
- RMBI Nasdaq
- ADCT Nasdaq
- Market Cap
- RMBI 128.3M
- ADCT 143.1M
- IPO Year
- RMBI 2019
- ADCT 2020
- Fundamental
- Price
- RMBI $12.75
- ADCT $1.36
- Analyst Decision
- RMBI
- ADCT Strong Buy
- Analyst Count
- RMBI 0
- ADCT 5
- Target Price
- RMBI N/A
- ADCT $7.75
- AVG Volume (30 Days)
- RMBI 28.9K
- ADCT 336.9K
- Earning Date
- RMBI 04-24-2025
- ADCT 03-27-2025
- Dividend Yield
- RMBI 4.69%
- ADCT N/A
- EPS Growth
- RMBI 1.10
- ADCT N/A
- EPS
- RMBI 0.92
- ADCT N/A
- Revenue
- RMBI $42,915,048.00
- ADCT $70,837,000.00
- Revenue This Year
- RMBI N/A
- ADCT $11.56
- Revenue Next Year
- RMBI N/A
- ADCT $17.03
- P/E Ratio
- RMBI $13.91
- ADCT N/A
- Revenue Growth
- RMBI 2.81
- ADCT 1.84
- 52 Week Low
- RMBI $10.15
- ADCT $1.28
- 52 Week High
- RMBI $15.15
- ADCT $5.38
- Technical
- Relative Strength Index (RSI)
- RMBI 48.63
- ADCT 33.56
- Support Level
- RMBI $12.60
- ADCT $1.28
- Resistance Level
- RMBI $13.40
- ADCT $1.68
- Average True Range (ATR)
- RMBI 0.38
- ADCT 0.11
- MACD
- RMBI 0.08
- ADCT -0.04
- Stochastic Oscillator
- RMBI 52.90
- ADCT 10.08
About RMBI Richmond Mutual Bancorporation Inc.
Richmond Mutual Bancorp Inc is a United States-based banking company. Its principal business consists of attracting deposits from the general public & brokered deposits and investing those funds predominantly in loans secured by commercial and multi-family real estate, first mortgages on owner-occupied, one-to four-family residences, a variety of consumer loans, direct financing leases, and commercial and industrial loans.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.